News about "Kaivan Khavandi"

GSK's Efimosfermin Secures FDA Breakthrough and EMA PRIME Status for MASH Treatment

The dual regulatory designations from US FDA and European Medicines Agency fast-track development of GSK’s investigational liver therapy for metabolic dysfunction-associated steatohepatitis.

Kaivan Khavandi | 29/04/2026 | By News Bureau |  110

GSK Acquires 100 Percent Equity of 35Pharma for USD 950 Million

GSK completes acquisition of 35Pharma, adding HS235, a potential best-in-class therapy for Pulmonary Hypertension.

Kaivan Khavandi | 16/04/2026 | By News Bureau

GSK completes acquisition of RAPT Therapeutics

GSK has completed the acquisition of RAPT Therapeutics, adding ozureprubart, a long-acting anti-IgE monoclonal antibody, to its pipeline. The candidate is currently in phase-II(b) development for prophylactic protection against food allergens, strengthening GSK’s immunology portfolio.

Kaivan Khavandi | 05/03/2026 | By Akanki |  114

Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK

Frontier Biotech has granted GSK exclusive global rights to two siRNA drug candidates in a deal worth up to USD 1 billion, strengthening its international expansion and immunology pipeline focus.

Kaivan Khavandi | 25/02/2026 | By News Bureau |  228

GSK Wins EU Approval for Exdensur in Severe Asthma and CRSwNP

European Commission clears twice-yearly depemokimab for type 2 inflammation-driven severe asthma and chronic rhinosinusitis with nasal polyps, backed by positive Phase III SWIFT and ANCHOR data.

Kaivan Khavandi | 18/02/2026 | By News Bureau |  135

China Approves Trelegy Ellipta for Uncontrolled Asthma

China has approved Trelegy Ellipta for adults with uncontrolled asthma, extending its use beyond COPD and making it the only single-inhaler triple therapy for both conditions in the country.

Kaivan Khavandi | 27/01/2026 | By News Bureau |  195

Japan Approves Exdensur for Severe Asthma and Nasal Polyps

Japan has approved Exdensur (depemokimab) for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), marking the first ultra-long-acting biologic in the country, with approval supported by phase-III SWIFT and ANCHOR trial data demonstrating sustained efficacy with twice-yearly dosing.

Kaivan Khavandi | 07/01/2026 | By News Bureau |  285

China Approves Nucala from GSK for Adult COPD Treatment

China has approved Nucala (mepolizumab) for adult COPD, supported by phase-III MATINEE and METREX trials showing reduced exacerbations in patients with blood eosinophil counts from 150 cells/µL.

Kaivan Khavandi | 06/01/2026 | By News Bureau |  306

GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide

Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.

Kaivan Khavandi | 29/10/2025 | By Dineshwori |  268

GSK Completes Acquisition of Efimosfermin from Boston Pharmaceuticals for USD 2 Billion

GSK has completed its acquisition of efimosfermin alfa, a Phase III-ready investigational therapy for serious liver diseases, from Boston Pharmaceuticals in a deal worth up to USD 2 billion.

Kaivan Khavandi | 09/07/2025 | By Mrinmoy Dey |  333